Healthy Clinical Trial
— IGNUTOfficial title:
Glycemic and Insulinemic Index Determination of 2 Products: Fructilight® and A Fruit Fructo-Oligosaccharides in Sweet Matrix
| Verified date | April 2011 |
| Source | CRITT Bio-Industries |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | France : AFSSAPS |
| Study type | Interventional |
The aim of the study is to determine glycemic and insulinemic index of 2 sweet syrups : FructiLight® and fruit Fructo-oligosaccharides in sweet matrix compared to glucose.
| Status | Active, not recruiting |
| Enrollment | 12 |
| Est. completion date | May 2011 |
| Est. primary completion date | March 2011 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 50 Years |
| Eligibility |
Inclusion Criteria: - Aged between 18 to 50 years (limits included - With a BMI between 19 and 25 kg/m² (limits included) - Non-smoker - Non-menopausal female with reliable contraception for two cycles before the beginning of the study and agreeing to keep it during the entire duration of the study - Capable and willing to conform to the protocol and accepting to give his written informed consent - Registered to Social Security System - Accepting to be registered on the Volunteers in biomedical research file After biological analysis, the subjects will be included on the following criteria : - Fasting blood sugar level < 1,1 g/L - Blood sugar level 120 minutes after 75g glucose intake < 1.4 g/L - Complete blood count without significant clinically abnormality according to the investigator - ASAT < 1,55 µkat/L - ALAT < 1,7 µkat/L - GGT < 2,55 µkat/L - 45 < Creatinine < 104 µmol/L - 1.7 < Urea < 8.3 mmol/L Exclusion Criteria: - Known food allergy, in particular to one of the tested products' components or to related products - Personal history of hypercholesterolemia, high blood pressure, diabetes or glucose intolerance - Renal insufficiency - Liver disorders ongoing - Gastrointestinal disorders, clinically significant according the investigator - Use of medications which could affect lipidic or carbohydrate metabolism - Disease or medication with impact on nutrients digestion and absorption - Pregnant or breastfeeding women - General anaesthetic in the month before the study - Presenting a psychological or linguistic incapability to sign the informed consent - Refusing to sign the informed consent - Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision - Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros - Impossible to contact in case of emergency - Major or medical or surgical event with hospitalization in the last 3 months - Taking part in an-other clinical trial or being in the exclusion period of a previous clinical trial |
Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| France | Biofortis | Nantes | Pays de La Loire |
| Lead Sponsor | Collaborator |
|---|---|
| CRITT Bio-Industries | BioFortis, NUTRITIS |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Area Under the glycemia Curve over 120 min (AUC 0-120min) | Syrup glycemic response compare to glucose glycemic response. Measure with glucometer at time 15, 30, 45, 60, 90, 120 (and 180 minutes) after the intake of 50g of glucose equivalent from the products (syrup or glucose). AUC(0-120min) calculation is computed following the FAO recommendation (cf. FAO/WHO 1998), i.e. using the trapezoidal incremental method and not taking into account the area beneath the fasting concentration. | 120 minutes after intake by test | No |
| Secondary | Area Under the insulinemia Curve over 120 min (AUC 0-120min) | Syrup insulinemia response compare to glucose insulinemia response. Measure at time 15, 30, 45, 60, 90, 120 (and 180 minutes) after the intake of 50g of glucose equivalent from the products (syrup or glucose). AUC(0-120min) calculation is computed following the FAO recommendation (cf. FAO/WHO 1998), i.e. using the trapezoidal incremental method and not taking into account the area beneath the fasting concentration. | 120 minutes after intake by test | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |